A research team has discovered a new mechanism and drug combination strategy that can effectively treat osteoporosis, a ...

Studies by University of Birmingham researchers suggest that a naturally occurring peptide known as PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration), could represent a promising potential ...

Osteogenesis imperfecta (OI) refers to a group of rare genetic bone disorders that results in the formation of fragile bones. In patients with OI, the matrix that makes up the bone has been found to ...

Developmental dysplasia of the hip (DDH) is a polygenetic disorder that increases the risk of hip osteoarthritis.

Around 40% of adults worldwide are affected by osteopenia: a loss of bone mineral density. This condition is extremely common ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

Scientists have identified a little-known receptor, GPR133, as a powerful regulator of bone strength. By activating it with a newly discovered compound called AP503, they were able to boost bone ...

Anabolic agents work differently from other osteoporosis medications in that they don't just slow down bone loss — they can trigger the growth of new bone.

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, exited stealth mode today ...

Taking omega-3 and vitamin D supplements together may help reduce pain, slow biological aging, improve bone health, and help ...